Neuroimaging of COVID-19

Abstract

We review the wide variety of common neuroimaging manifestations related to coronavirus disease 2019 (COVID-19) and COVID therapies, grouping the entities by likely pathophysiology, recognizing that the etiology of many entities remains uncertain. Direct viral invasion likely contributes to olfactory bulb abnormalities. COVID meningoencephalitis may represent direct viral infection and/or autoimmune inflammation. Para-infectious inflammation and inflammatory demyelination at the time of infection are likely primary contributors to acute necrotizing encephalopathy, cytotoxic lesion of the corpus callosum, and diffuse white matter abnormality. Later postinfectious inflammation and demyelination may manifest as acute demyelinating encephalomyelitis, Guillain–Barré syndrome, or transverse myelitis. The hallmark vascular inflammation and coagulopathy of COVID-19 may produce acute ischemic infarction, microinfarction contributing to white matter abnormality, space-occupying hemorrhage or microhemorrhage, venous thrombosis, and posterior reversible encephalopathy syndrome. Adverse effects of therapies including zinc, chloroquine/hydroxychloroquine, antivirals, and vaccines, and current evidence regarding “long COVID” is briefly reviewed. Finally, we present a case of bacterial and fungal superinfection related to immune dysregulation from COVID.

Post-COVID central hypersomnia, a treatable trait in long COVID: 4 case reports

“…These mechanisms could explain a prolonged dysfunction of brainstem nuclei involved in sleep-wakefulness regulation ( 5 ). Although no routinely available paraclinical test can currently confirm the diagnosis of PCC, certain non-specific neuroimaging changes have been reported ( 6 ).…”

“…Although no routinely available paraclinical test can currently confirm the diagnosis of PCC, certain non-specific neuroimaging changes have been reported (6).…”